|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009402,
umls-concept:C0021756,
umls-concept:C0036525,
umls-concept:C0045093,
umls-concept:C0079460,
umls-concept:C0205263,
umls-concept:C0205470,
umls-concept:C0278484,
umls-concept:C0332283,
umls-concept:C0441655,
umls-concept:C0442821,
umls-concept:C0443315,
umls-concept:C1516213,
umls-concept:C1522484
|
|
pubmed:issue |
35
|
|
pubmed:dateCreated |
2005-12-12
|
|
pubmed:abstractText |
Tumor cell killing by anticancer drugs may be supported by their immuno- and pharmacologic effects. Chemotherapy is in fact able to (A) upregulate tumor-associated antigen expression, including carcinoembryonic antigen (CEA) or other target molecules such as thymidylate synthase (TS); and (B) downregulate tumor cell resistance to the death signals induced by tumor antigen-specific cytotoxic T lymphocytes. This provides the rationale for combining chemo- and immunotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Carcinoembryonic Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte-Macrophage...,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidylate Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine,
http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AquinoAngeloA,
pubmed-author:BonmassarEnzoE,
pubmed-author:CorrealePierpaoloP,
pubmed-author:CusiMaria GraziaMG,
pubmed-author:Del VecchioMaria TeresaMT,
pubmed-author:FerrariFrancescoF,
pubmed-author:FranciniGuidoG,
pubmed-author:GiorgiGiorgioG,
pubmed-author:IntriviciChiaraC,
pubmed-author:MarsiliStefaniaS,
pubmed-author:MicheliLuciaL,
pubmed-author:NenciniCristinaC,
pubmed-author:PlacaMarco LaML,
pubmed-author:TsangKwong YokKY
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
10
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
8950-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16061910-Aged,
pubmed-meshheading:16061910-Antigens, Neoplasm,
pubmed-meshheading:16061910-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16061910-Carcinoembryonic Antigen,
pubmed-meshheading:16061910-Colonic Neoplasms,
pubmed-meshheading:16061910-Colorectal Neoplasms,
pubmed-meshheading:16061910-Cytotoxicity, Immunologic,
pubmed-meshheading:16061910-Deoxycytidine,
pubmed-meshheading:16061910-Disease Progression,
pubmed-meshheading:16061910-Female,
pubmed-meshheading:16061910-Flow Cytometry,
pubmed-meshheading:16061910-Fluorouracil,
pubmed-meshheading:16061910-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:16061910-Humans,
pubmed-meshheading:16061910-Immunotherapy,
pubmed-meshheading:16061910-Infusions, Intravenous,
pubmed-meshheading:16061910-Interleukin-2,
pubmed-meshheading:16061910-Leucovorin,
pubmed-meshheading:16061910-Male,
pubmed-meshheading:16061910-Organoplatinum Compounds,
pubmed-meshheading:16061910-T-Lymphocytes, Regulatory,
pubmed-meshheading:16061910-Thymidylate Synthase,
pubmed-meshheading:16061910-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
|
|
pubmed:affiliation |
Section of Medical Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
